Canaccord analyst William Plovanic raised the firm’s price target on iRhythm to $137 from $122 and keeps a Buy rating on the shares. The firm believes the risk/reward ratio is very favorable and believe the recent pullback is an opportunity for longer-term investors to buy the stock; especially once Q3/24 has been reported as they see it as a clearing event for both regulatory/ legal and financial overhangs.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm received regulatory approval from Japanese PMDA for Zio ECG system
- iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
- iRhythm unveils data on real-world performance of Zio Monitor
- iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
- iRhythm Technologies Strikes Advanced Tech Licensing Deal